DrugPatentWatch Database Preview
Drugs in Development Information for Gossypol
Development status for investigational drug Gossypol: Sponsors, patents, clinical trial progress
Gossypol is an investigational drug.
There have been 10 clinical trials for Gossypol.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Third Military Medical University.
There are seven hundred and fifty-eight US patents protecting this investigational drug and four international patents.
Summary for Gossypol
| US Patents | 758 |
| International Patents | 4,809 |
| US Patent Applications | 1,343 |
| WIPO Patent Applications | 952 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2013-09-01) |
| Vendors | 79 |
Recent Clinical Trials for Gossypol
| Title | Sponsor | Phase |
|---|---|---|
| R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | Mayo Clinic | Phase 1/Phase 2 |
| Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Gossypol
Top disease conditions for Gossypol
Top clinical trial sponsors for Gossypol
US Patents for Gossypol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Gossypol | See Pricing | Heterocyclic compounds useful in the treatment of disease | Epigen Biosciences, Inc. (San Diego, CA) | See Pricing |
| Gossypol | See Pricing | Pyrazol-3-ones that activate pro-apoptotic BAX | Dana-Farber Cancer Institute, Inc. (Boston, MA) | See Pricing |
| Gossypol | See Pricing | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | See Pricing |
| Gossypol | See Pricing | Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor | The Regents of the University of California (Oakland, CA) | See Pricing |
| Gossypol | See Pricing | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) | See Pricing |
| Gossypol | See Pricing | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy | University of Georgia Research Foundation Inc. (Athens, GA) | See Pricing |
| Gossypol | See Pricing | Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids at the sn-2 position | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Acton, AU) GRAINS RESEARCH AND DEVELOPMENT CORPORATION (Barton, AU) NUSEED PTY LTD. (Laverton North, AU) | See Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Gossypol
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Gossypol | Australia | 2014232383 | 2033-03-15 | See Pricing |
| Gossypol | Australia | 2019202731 | 2033-03-15 | See Pricing |
| Gossypol | Brazil | 112015023267 | 2033-03-15 | See Pricing |
| Gossypol | Canada | 2906931 | 2033-03-15 | See Pricing |
| Gossypol | China | 105142635 | 2033-03-15 | See Pricing |
| Gossypol | Eurasian Patent Organization | 201591607 | 2033-03-15 | See Pricing |
| Gossypol | European Patent Office | 2988743 | 2033-03-15 | See Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
